Jacobio Pharmaceuticals Group Co., Ltd. (JACOBIO-B) disclosed a next-day return confirming a share repurchase on 11 May 2026. Key data follow:

• Volume and price: 75,600 ordinary shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 6.15 to HKD 6.18, resulting in a volume-weighted average cost of HKD 6.17 per share. Total cash outflow was HKD 0.47 million.

• Impact on capital structure: The transaction reduced outstanding shares (excluding treasury stock) by 0.00963%, from 784.93 million to 784.85 million. Treasury shares increased from 6.83 million to 6.91 million, leaving the issuer’s total share count unchanged at 791.76 million.

• Repurchase mandate utilisation: Since the current mandate was approved on 10 June 2025, Jacobio Pharmaceuticals has bought back 3.89 million shares, equal to 0.49% of the shares outstanding on the mandate date. The company is authorised to repurchase up to 78.87 million shares under this mandate.

• Post-repurchase restrictions: In line with Hong Kong Listing Rules, Jacobio Pharmaceuticals is restricted from issuing new shares or transferring treasury shares until 10 June 2026, unless prior exchange approval is obtained.

The company confirmed that the buyback complied with all Main Board requirements and that no repurchased shares have been cancelled to date; all remain in the treasury account.